What is new in augmented renal clearance in septic patients?
L Baptista, I Moura, CM Silva, JP Baptista - Current Infectious Disease …, 2023 - Springer
Abstract Purpose of Review In this narrative review encompassing relevant scientific
publications regarding critically ill patients in the last 5 years, we discuss key questions …
publications regarding critically ill patients in the last 5 years, we discuss key questions …
Identifying optimal dosing strategies for meropenem in the paediatric intensive care unit through modelling and simulation
R Morales Junior, T Mizuno, KM Paice… - Journal of …, 2024 - academic.oup.com
Background Meropenem, a β-lactam antibiotic commonly prescribed for severe infections,
poses dosing challenges in critically ill patients due to highly variable pharmacokinetics …
poses dosing challenges in critically ill patients due to highly variable pharmacokinetics …
Meropenem PK/PD Variability and Renal Function:“We Go Together”
J Angelini, S Giuliano, S Flammini, A Pagotto, F Lo Re… - Pharmaceutics, 2023 - mdpi.com
Background: Meropenem is a carbapenem antibiotic widely employed for serious bacterial
infections. Therapeutic drug monitoring (TDM) is a strategy to optimize dosing, especially in …
infections. Therapeutic drug monitoring (TDM) is a strategy to optimize dosing, especially in …
Application of Monte Carlo simulation to optimise the dosage regimen of meropenem in patients with augmented renal clearance for Pseudomonas aeruginosa …
J Hou, M Zhang, SQ Ma, RN Cong, JF Li - Heliyon, 2024 - cell.com
Objective To optimise the dosing regimen of meropenem for treating Pseudomonas
aeruginosa (PA) infections in critically ill patients with augmented renal clearance (ARC) …
aeruginosa (PA) infections in critically ill patients with augmented renal clearance (ARC) …
Does Cytokine-Release Syndrome Induced by CAR T-Cell Treatment Have an Impact on the Pharmacokinetics of Meropenem and Piperacillin/Tazobactam in Patients …
C Liu, PG Cojutti, M Giannella, M Roberto, B Casadei… - Pharmaceutics, 2023 - mdpi.com
Chimeric antigen receptor (CAR) T-cell therapy is a promising approach for some
relapse/refractory hematological B-cell malignancies; however, in most patients, cytokine …
relapse/refractory hematological B-cell malignancies; however, in most patients, cytokine …
Interações medicamentosa mediadas pela CYP 450 em pacientes críticos: ênfase em antifúngicos triazólicos
SS de Moraes, LRA Manaças… - Revista Eletrônica Acervo …, 2023 - acervomais.com.br
objetivo: Fornecer informações sobre as principais alterações fisiológicas que podem
influenciar as propriedades farmacológicas em pacientes críticos e das interações …
influenciar as propriedades farmacológicas em pacientes críticos e das interações …